Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADxE + FLADx
- Development stage
- Preclinical
- Lead developer
- Västra Götalandsregionen
- Modality
- Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
ADxE + FLADx appears to be a combination of chemotherapy regimens used in the treatment of pediatric acute myeloid leukemia (AML). Based on available information, these are different induction courses used in AML treatment protocols, with research investigating whether FLADx has higher efficacy than ADxE when given as the second induction course.
Beyond the preview
Go deeper on ADxE + FLADx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADxE + FLADx.